An exploratory study recorded changing brain signals during combined psilocybin and midazolam administration, without validating a universal marker of consciousness or memory.
What the source reports
Healthy volunteers received oral psilocybin with intravenous midazolam in an open-label pilot. Early recordings, when midazolam effects predominated, showed increased beta power and a reduced spectral exponent. Later psychedelic effects accompanied different power, complexity and spectral-exponent patterns. Models incorporated observed sedation and subjective psychedelic ratings.
Limits and uncertainty
The small sample, open-label design and individual variability limit causal separation of the drugs. EEG complexity depends partly on processing choices and spectral power. A signal associated with a subjective state is not direct proof of later recall, and this physiological analysis did not establish treatment efficacy.
Implications for forensic review
For testimony about amnesia or awareness, distinguish behavior during exposure, electrical measurements and later memory reports. Those endpoints can diverge. The study supports careful description of a combined-drug experiment, rather than using one EEG feature to decide whether a person experienced or remembered a particular event.
Source and related reading
Source reviewed: Electrophysiological effects of psilocybin co administered with midazolam (PMC13004994). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Midazolam Partly Impaired Memory While a Conscious Psilocybin Experience Continued.
Leave a Reply